Targeting an RNA Methyltransferase to Treat Neuroblastoma
Grant awarded in 2024 following an in-depth review of high-quality funding applications by our world class Scientific Advisory Board. Associate Professor Tao Liu from the Children’s Cancer Institute proposal researched the potential to improve patient outcomes from neuroblastoma treatments by targeting an RNA Methyltransferase. Targeting an RNA Methyltransferase to Treat Neuroblastoma Despite the availability of […]
Enhancing Immunotherapy in High-Risk Neuroblastoma
Grant Awarded in 2024 following an in-depth review of high-quality funding applications by our world class Scientific Advisory Board. Dr. Emmy Dolman from the Children’s Cancer Institute will study the potential for enhancing immunotherapy to treat neuroblastoma. Unlocking Immune Escape: Enhancing Immunotherapy in High-Risk Neuroblastoma via Targeted AURKA Degradation Immunotherapy has transformed cancer treatment for […]
Developing Humanised Immunocompetent Mouse Models of High-Risk Neuroblastoma
Grant awarded in 2024 following an in-depth review of grant proposals by our world-class Scientific Advisory Board. Dr. Toby Trahair from Sydney Children’s Hospital studied the potential for tailored treatment programmes by continuing developments in the field of immuno-oncology. Developing Humanised Immunocompetent Mouse Models of High-Risk Neuroblastoma For over a decade, neuroblastoma researchers have worked to develop patient-derived neuroblastoma models in order to study neuroblastoma biology, to […]
AMXT 1501 and DFMO combination therapy
Grant Recipients 2025 Professor Michelle Haber and Professor Murray Norris. Research Project Professor Michelle Haber’s and Professor Murray Norris’s team at Children’s Cancer Institute discovered that a drug called DFMO was much more effective at killing neuroblastoma cells with the addition of a polyamine uptake inhibitor called AMXT 1501 (developed by Aminex Therapeutics). Should their […]
Support research to cure high-risk neuroblastoma
Dr. Zsuzsanna Nagy, initiated this conduct ground-breaking research, which seeks to find a new treatment option that would improve the long-term survival of children suffering from high-risk neuroblastoma. Following Dr. Nagy’s move to the United States, the project is now being led by Dr. Kevin Wang. Dr. Kevin Wang obtained his PhD from Lens Research […]
Venetoclax combination study
Our world class Scientific Advisory Board strongly recommended we fund this project due to the quality of research and potential to make a difference to treatments. A promising new drug combination for aggressive neuroblastoma Many of our supporters will be familiar with Dr. Jamie Fletcher from Children’s Cancer Institute and Dr. Toby Trahair from Sydney Children’s Hospital, and the incredible research they lead on […]
High-risk neuroblastoma with TERT oncogene
High-risk neuroblastoma cases with TERT oncogene rearrangement Neuroblastoma is the most common solid tumour in early childhood and accounts for 15% of all childhood cancer death. Approximately a quarter of high-risk neuroblastoma is caused by TERT oncogene rearrangement. Children with this subtype of neuroblastoma have less than 40% survival rate and are typically treated with […]